David Spiegel, MD
Psychiatry · Norfolk, VANPI 1518934728
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $511,195 of the $564,765 with a category attached, or 90.5%. 17 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 33.3% of the total. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,049 payments — averaging $538.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$188K
- Alkermes, Inc.$168K
- AbbVie$132K
- Otsuka America Pharmaceutical, Inc.$65K
- Vanda Pharmaceuticals Inc.$6K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $3K from 11 others
What the payments were for
- Consulting fees$13,9822%
- Speaking & faculty fees$511,19591%
- Travel & lodging$23,8554%
- Food & beverage$15,5823%
- Education$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 214 | $188,333 |
| Alkermes, Inc. | 188 | $168,367 |
| AbbVie(2 entities) | 350 | $132,130 |
| Otsuka America Pharmaceutical, Inc. | 122 | $65,404 |
| Vanda Pharmaceuticals Inc. | 11 | $6,489 |
| E.r. Squibb & Sons, L.L.C. | 15 | $1,379 |
| Lundbeck LLC | 55 | $785 |
| Sunovion Pharmaceuticals Inc. | 35 | $467 |
| Eisai Inc. | 14 | $453 |
| Johnson & Johnson | 14 | $257 |
| Teva Pharmaceuticals USA, Inc. | 9 | $181 |
| Neurocrine Biosciences, Inc. | 7 | $137 |
| Axsome Therapeutics, Inc. | 5 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $103 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $68 |
| Supernus Pharmaceuticals, Inc. | 1 | $60 |
| Sage Therapeutics, LLC | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$543,627
- CAPLYTA$186,398
- VRAYLAR$128,165
- ARISTADA$123,376
- REXULTI$62,674
- ARISTADA INITIO$30,844
- Fanapt$6,351
- ABILIFY MAINTENA$1,053
- Leqembi$108
- COBENFY$107
How this compares
$564,765 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 25 | $41,252 |
| VraylarCariprazine Hcl | 11 | $14,711 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,904 |
| Protriptyline Hcl | 15 | $5,320 |
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 20 | $3,514 |
| Aripiprazole | 12 | $3,444 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $3,319 |
| Olanzapine | 28 | $2,899 |
| Quetiapine Fumarate | 25 | $1,909 |
| Gabapentin | 75 | $1,396 |
| Carbamazepine ErCarbamazepine | 14 | $1,166 |
| Modafinil | 23 | $1,079 |
| Alprazolam ErAlprazolam | 20 | $997 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 53 | $991 |
| Duloxetine Hcl | 17 | $986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $188,333 | $41,25225 claims |
| AbbVieVraylar | $132,130 | $14,71111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $103 | $6,90413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Norfolk
- James RapleyNorfolk$98K
- Christine TrumanNorfolk$13K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- William YetterVirginia Beach$312K
- Anita ClaytonCharlottesville$260K
- Robert GardellaStaunton$201K
- Timothy KaneStaunton$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.